NIH Research Reveals Why GLP-1 Weight Loss Drugs Plateau and How to Extend Their Effects
Scientists funded by the National Institutes of Health have discovered why GLP-1 based weight loss medications often reach a plateau over time. The research reveals that semaglutide, the active ingredient in Ozempic and Wegovy, triggers varying responses in the brain cells responsible for controlling appetite.
The findings offer insight into why these medications do not produce identical results for every patient. The study found that individual differences in how brain cells respond to the drug may explain the inconsistency in weight loss outcomes.
Most notably, researchers identified a potential method to extend the drugs' effectiveness. This could help patients who have hit a weight loss plateau push beyond their current results and continue making progress.
This research represents a significant step toward understanding how GLP-1 receptor agonists work at the cellular level, which may ultimately lead to more personalized approaches to obesity treatment.